DexCom (NASDAQ:DXCM) Given New $85.00 Price Target at JPMorgan Chase & Co.

DexCom (NASDAQ:DXCM) had its target price upped by JPMorgan Chase & Co. from $82.00 to $85.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a neutral rating on the medical device company’s stock.

Other equities research analysts also recently issued reports about the stock. Argus boosted their target price on shares of DexCom from $86.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. TD Cowen reaffirmed a “buy” rating and set a $95.00 price target on shares of DexCom in a research report on Friday, September 18th. UBS Group set a $96.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Tuesday, July 28th. BTIG Research lifted their price target on shares of DexCom from $90.00 to $96.00 and gave the company a “buy” rating in a report on Monday, October 12th. Finally, Citigroup reiterated a “buy” rating and issued a $88.00 price target (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, DexCom presently has an average rating of “Buy” and a consensus price target of $92.91.

DexCom Stock Up 3.0%

Shares of NASDAQ:DXCM opened at $82.29 on Friday. The stock’s 50-day moving average price is $85.82 and its two-hundred day moving average price is $74.65. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. DexCom has a 12-month low of $54.11 and a 12-month high of $92.59. The firm has a market cap of $31.05 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 1.34 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.68 by $0.05. DexCom had a return on equity of 36.96% and a net margin of 19.42%. The company had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the previous year, the business earned $0.61 EPS. The firm’s revenue was up 11.1% on a year-over-year basis. On average, research analysts forecast that DexCom will post 2.64 EPS for the current year.

Insider Buying and Selling

In other news, Director Mark Foletta sold 2,000 shares of DexCom stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $85.32, for a total value of $170,640.00. Following the transaction, the director directly owned 48,852 shares of the company’s stock, valued at $4,168,052.64. The trade was a 3.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $85.48, for a total value of $145,316.00. Following the sale, the executive vice president owned 98,185 shares of the company’s stock, valued at $8,392,853.80. The trade was a 1.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 24,822 shares of company stock worth $2,090,833. Corporate insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Covestor Ltd increased its holdings in DexCom by 79.6% in the 3rd quarter. Covestor Ltd now owns 1,282 shares of the medical device company’s stock valued at $111,000 after purchasing an additional 568 shares in the last quarter. Caldwell Trust Co lifted its stake in shares of DexCom by 1.8% during the third quarter. Caldwell Trust Co now owns 13,732 shares of the medical device company’s stock worth $1,185,000 after purchasing an additional 241 shares in the last quarter. Rakuten Investment Management Inc. lifted its stake in shares of DexCom by 8.7% during the third quarter. Rakuten Investment Management Inc. now owns 101,020 shares of the medical device company’s stock worth $8,752,000 after purchasing an additional 8,108 shares in the last quarter. Factory Mutual Insurance Co. boosted its position in shares of DexCom by 4.8% in the third quarter. Factory Mutual Insurance Co. now owns 563,383 shares of the medical device company’s stock worth $48,614,000 after buying an additional 25,553 shares during the period. Finally, Signature Equity Partners LLC boosted its position in shares of DexCom by 97.3% in the third quarter. Signature Equity Partners LLC now owns 436 shares of the medical device company’s stock worth $38,000 after buying an additional 215 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.